Table 2.
Model performance for cohorts described in Table 1.
| A: High-risk OC + OPMD |
B: High-risk CV OC + OPMD |
C: Average-risk OC only | D: Average-risk Technical validation | |
|---|---|---|---|---|
| ROC AUC | 0.87 | 0.87 | 0.90 | n/a |
| Sensitivity | 81% | 83% | 76% | n/a |
| Specificity | 85% | 79% | 88% | 97.9% |
| True positives by stage | ||||
| OPMD | 7/10 | 11/14 | n/a | n/a |
| OC Stage 1 | 12/13 | 11/14 | 12/14 | n/a |
| OC Stage 2 | 11/16 | 12/17 | 11/16 | n/a |
| OC Stage 3 | 1/2 | 2/2 | 2/3 | n/a |
| OC Stage 4 | 13/14 | 18/19 | 10/14 | n/a |
For sensitivity and specificity, we used the standard default clinical decision threshold of prediction probability = 0.5. Technical validation for the average-risk cohort D was performed using the model developed for Cohort A.